Amphastar Pharmaceuticals (AMPH) Net Cash Flow (2013 - 2026)

Amphastar Pharmaceuticals' Net Cash Flow history runs 14 years deep, the most recent figure standing at $900000.0 for Q1 2026.

• On a quarterly basis, Net Cash Flow fell 97.1% year-over-year to $900000.0 in Q1 2026; TTM through Mar 2026 was -$11.8 million, a 35.85% increase from a year earlier, with the FY2025 full-year figure at $18.4 million, up 144.68% from the prior year.
• Net Cash Flow grew to $900000.0 in Q1 2026 per AMPH's latest filing, from -$46.1 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $119.8 million in Q3 2023 and bottomed at -$126.3 million in Q4 2023.
• The 5-year median for Net Cash Flow is $900000.0 (2026), against an average of $2.7 million.
• Biggest YoY gain for Net Cash Flow was 1459.14% in 2023; the steepest drop was 10738.45% in 2023.
• Year by year, Net Cash Flow stood at -$1.2 million in 2022, then plunged by 10738.45% to -$126.3 million in 2023, then jumped by 67.93% to -$40.5 million in 2024, then declined by 13.79% to -$46.1 million in 2025, then jumped by 101.95% to $900000.0 in 2026.
• Per Business Quant, the three latest AMPH Net Cash Flow figures stand at $900000.0 (Q1 2026), -$46.1 million (Q4 2025), and $28.6 million (Q3 2025).